CClinicalTrials.gg
RecruitingNCT03299179Updated Dec 6, 2023

The Effects of the Female Hormones on Cerebral Perfusion

An observational study in Cerebral Perfusion, Contraception and Menstrual Cycle, sponsored by University Ghent. Recruiting at 1 site in Belgium. Open to female participants aged 18 Years to 25 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-06.

Sponsored by University Ghent · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
62
Ages
18 Years to 25 Years
Sex
Female
01

Study summary

Measuring brain perfusion is biased by a inter- and intrasubject variability, caused by physiological and lifestyle factors. In this study, the investigators want to investigate the variations in cerebral perfusion and other brain parameters (grey matter, resting-state brain activity, brain connectivity and white matter diffusion) caused by the female sex hormones and hormonal contraception.

02

Conditions studied

  • Cerebral Perfusion
  • Contraception
  • Menstrual Cycle
03

Who can participate

Ages eligible
18 Years to 25 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

30 healthy young volunteers, either using no hormonal anti-conception, either using Deso20 as anti-conception.

Inclusion criteria

  • Bachelor or Master student
  • Minimum of 3 months not using contraception of using Deso20

Exclusion criteria

Exclusion Criteria:

  • No informed consent
  • MRI-contraindications
  • Claustrophobia
  • Pregnancy or breastfeeding
  • Chronic diseases and chronic medication use
  • Smoker
  • Drug use
  • Abuse of alcohol and caffeine
04

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
62 participants (estimated)
Patient registry
No

Groups and cohorts

  • Natural cycle

    15 female volunteers, not using hormonal contraception, will be scanned during 3 menstrual cycles. During each cycle, the volunteers will be scanned 3 times: during the follicular phase, during ovulation and during luteal phase.

    Device: MRI scan · Device: Physiological monitoring · Biological: Blood sample · Device: Blood pressure measurement · Device: Body temperature · Other: Questionnaires · Diagnostic Test: Pregnancy test

  • Anti-conception

    15 female volunteers, using hormonal contraception pill Deso 20, will be scanned during 3 menstrual cycles. During each cycle, the volunteers will be scanned 2 times: during the pill-week and during the pill-free week.

    Device: MRI scan · Device: Physiological monitoring · Biological: Blood sample · Device: Blood pressure measurement · Device: Body temperature · Other: Questionnaires

Interventions

  • DeviceMRI scan

    Several MRI scan modalities: MPRAGE (structural scan), arterial spin labeling (cerebral perfusion), resting state functional-MRI (fMRI, cerebral activity) and diffusion MRI (white matter diffusion and white matter tracts).

  • DevicePhysiological monitoring

    During MRI: heart rate, end-tidal carbon dioxide (CO2), respiratory rate and skin conductance

  • BiologicalBlood sample

    Blood sample after MRI-session: measurement of hematocrit, hemoglobin, estradiol, progesterone, follicle stimulation hormone and luteinizing hormone.

  • DeviceBlood pressure measurement

    Measuring blood pressure before and after MRI-scan

  • DeviceBody temperature

    Measuring body temperature before and after MRI-scan

  • OtherQuestionnaires

    Questionnaires at the start of the study on lifestyle. Additionally, a questionnaire before each scan session on the actual state of the volunteer (e.g. mood, caffeine consumption, alcohol, medication, etc.)

  • Diagnostic testPregnancy test

    Test for pregnancy using a pregnancy dipstick test

05

What researchers measure

Primary outcomes

  1. Regional cerebral perfusion (ml/100g/min): natural versus contraception

    Differences in regional perfusion between volunteers of the natural cycle group versus the volunteers using contraception

    Time frame: measured during scan-session

  2. Regional cerebral perfusion (ml/100g/min) variations during natural menstrual cycle

    Variations in cerebral perfusion during the menstrual cycle: follicular phase versus ovulation versus luteal phase in the natural cycle group, correlated with female hormones measured in blood sample

    Time frame: measured during scan-session

  3. Regional cerebral perfusion (ml/100g/min) variations during menstrual cycle using contraception

    Variations in cerebral perfusion during the menstrual cycle: pill-week versus pill-free week in the contraception group, correlated with female hormones measured in blood sample

    Time frame: measured during scan-session

Secondary outcomes

  1. Regional grey matter volume (mm³): natural versus contraception

    Differences in regional grey matter volume between volunteers of the natural cycle group versus the volunteers using contraception

    Time frame: measured during scan-session

  2. Regional grey matter volume (mm³) variations during natural menstrual cycle

    Variations during the menstrual cycle: follicular phase versus ovulation versus luteal phase in the natural cycle group, correlated with female hormones measured in blood sample

    Time frame: measured during scan-session

  3. Regional grey matter volume (mm³) variations during menstrual cycle using contraception

    Variations in grey matter volume during the menstrual cycle: pill-week versus pill-free week in the contraception group, correlated with female hormones measured in blood sample

    Time frame: measured during scan-session

  4. Resting state brain activity: natural versus contraception

    Differences in resting state brain activity between volunteers of the natural cycle group versus the volunteers using contraception

    Time frame: measured during scan-session

  5. Resting state brain activity variations during natural menstrual cycle

    Variations in resting state brain activity during the menstrual cycle: follicular phase versus ovulation versus luteal phase in the natural cycle group, correlated with female hormones measured in blood sample

    Time frame: measured during scan-session

  6. Resting state brain activity variations during menstrual cycle using contraception

    Variations in resting state brain activity during the menstrual cycle: pill-week versus pill-free week in the contraception group, correlated with female hormones measured in blood sample

    Time frame: measured during scan-session

  7. Cerebral diffusion properties: natural versus contraception

    Differences in diffusion properties (Mean Diffusivity(MD)/Apparent Diffusion Coefficient (ADC)/fractional Anisotropy(FA)) between volunteers of the natural cycle group versus the volunteers using contraception

    Time frame: measured during scan-session

  8. Cerebral diffusion properties variations during natural menstrual cycle

    Variations in diffusion properties (MD/ADC/FA) during the menstrual cycle: follicular phase versus ovulation versus luteal phase in the natural cycle group, correlated with female hormones measured in blood sample

    Time frame: measured during scan-session

  9. Cerebral diffusion properties variations during menstrual cycle using contraception

    Variations in diffusion properties (MD/ADC/FA) during the menstrual cycle: pill-week versus pill-free week in the contraception group, correlated with female hormones measured in blood sample

    Time frame: measured during scan-session

06

Study locations

1 of 1 sites recruiting
  • Ghent University Hospital
    Ghent, 9000, Belgium
    Recruiting
07

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03299179
Lead sponsor
University Ghent
Responsible party
Sponsor
First posted
Oct 2, 2017
Start date
Oct 3, 2016
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Dec 6, 2023

Study contacts

Patricia Clement, Msc
Contact
patricia.clement@ugent.be
9 332 1330 ext. +32
Eric Achten, MD, PhD
principal investigator · University Hospital, Ghent

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion